- Home
- SCTX vs VMD Comparison
SCTX vs VMD Comparison
Compare SCTX & VMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SCTX | VMD |
|---|---|---|
| Founded | 2017 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.2M | 351.6M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SCTX | VMD |
|---|---|---|
| Price | $16.15 | $9.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $57.00 | $12.00 |
| AVG Volume (30 Days) | ★ 346.2K | 197.3K |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.14 |
| EPS | N/A | ★ 0.24 |
| Revenue | N/A | ★ $270,280,000.00 |
| Revenue This Year | N/A | $17.63 |
| Revenue Next Year | N/A | $11.23 |
| P/E Ratio | ★ N/A | $37.83 |
| Revenue Growth | N/A | ★ 20.52 |
| 52 Week Low | $13.50 | $6.18 |
| 52 Week High | $39.60 | $12.61 |
Technical Indicators
Market Signals| Indicator | SCTX | VMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 45.29 |
| Support Level | $13.90 | $8.55 |
| Resistance Level | $22.07 | $10.07 |
| Average True Range (ATR) | 1.58 | 0.36 |
| MACD | 0.33 | -0.08 |
| Stochastic Oscillator | 52.49 | 29.67 |
Price Performance
Historical ComparisonAbout SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.